Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002996 · ClinicalTrials.gov registry record · Phase 2
Flecainide in Treating Patients With Chronic Neuropathic Pain
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00002996 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 20 participants.
The verdict
NCT00002996, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS.
Interventions
- DRUG flecainide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1998-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002996
The ClinicalTrials.gov registry entry for NCT00002996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which flecainide acetate is the first listed.
NCT00002996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002996 about?
NCT00002996 is a clinical study titled "Flecainide in Treating Patients With Chronic Neuropathic Pain". RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS.
What is the current status of trial NCT00002996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1998-05-04.
What interventions are being tested in trial NCT00002996?
The interventions under investigation include: flecainide acetate (DRUG).
Who is sponsoring clinical trial NCT00002996?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.